You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Subretinal Fluid

Showing 1 - 25 of 5,955
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Recruiting
  • Polypoidal Choroidal Vasculopathy
  • +2 more
  • Intravitreal aflibercept injection
  • Seoul, Korea, Republic of
    Jae Hui Kim
Dec 20, 2022

Perfluorooctyl Bromide Which Empowers Liquid to Flat Detached

Recruiting
  • Retinal Disease
    • Cairo, Kubri EL Kubba, Egypt
      Girgis Boules
    Jan 24, 2023

    Acute Central Serous Retinopathy With Subretinal Fluid Trial in Minya (Micropulse laser)

    Completed
    • Acute Central Serous Retinopathy With Subretinal Fluid
    • Micropulse laser
    • Minya, Minia, Egypt
      Minia University Hospital
    Sep 8, 2022

    Vitreomacular Traction, Subretinal Edema Trial in Norfolk (Eplerenone)

    Terminated
    • Vitreomacular Traction
    • Subretinal Edema
    • Norfolk, Virginia
      Wagner Macula & Retina Center
    Jan 6, 2021

    Retinal Vein Occlusion, Diabetic Macular Edema Trial in Beverly Hills, Boston (KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0%

    Completed
    Has Results
    • Retinal Vein Occlusion
    • Diabetic Macular Edema
    • KPI-121 0.25% Ophthalmic Suspension
    • KPI-121 1.0% Ophthalmic Suspension
    • Beverly Hills, California
    • +1 more
    Dec 9, 2020

    Single Injection of Faricimab for nAMD With Persisting Fluid

    Active, not recruiting
    • Neovascular Age-related Macular Degeneration
    • Glostrup, Denmark
      Miklos Schneider
    Nov 3, 2023

    Central Serous Chorioretinopathy Trial (100µm laser spot diameter micropulse laser, 200µm laser spot diameter micropulse laser)

    Not yet recruiting
    • Central Serous Chorioretinopathy
    • 100μm laser spot diameter micropulse laser
    • 200μm laser spot diameter micropulse laser
    • (no location specified)
    Jan 13, 2023

    Retina Detachment Trial in Brescia (Scleral Buckling, Drainage-Injection-Pneumoretinopexy)

    Completed
    • Retina Detachment
    • Scleral Buckling
    • Drainage-Injection-Pneumoretinopexy
    • Brescia, BS, Italy
      Spedali Civili di Brescia
    Oct 23, 2019

    Choroidal Neovascularization Trial in Sao Paulo (bevacizumab)

    Completed
    • Choroidal Neovascularization
    • Sao Paulo, Brazil
      Hospital das Clínicas- University of Sao Paulo
    Jan 4, 2022

    Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept 40 MG/ML
    • Faricimab 120 MG/ML
    • Graz, Styria, Austria
      Department of Ophthalmolgy, Medical University Graz
    Jul 3, 2023

    Age-Related Macular Degeneration Trial in Beijing (KH631)

    Not yet recruiting
    • Age-Related Macular Degeneration
    • Beijing, China
      Beijing Tongren Hospital, Capital Medical University
    Jan 3, 2023

    Diabetic Macular Edema Trial (RC-28E, Aflibercept)

    Not yet recruiting
    • Diabetic Macular Edema
    • RC-28E
    • Aflibercept
    • (no location specified)
    May 30, 2023

    Achromatopsia Trial in Tuebingen (rAAV.hCNGA3)

    Recruiting
    • Achromatopsia
    • Tuebingen, Germany
      University Hospital Tuebingen, Center for Ophthalmology
    Dec 7, 2022

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Diabetic Retinopathy, Vitreomacular Traction Trial in Minya (Methotrexate 25 MG/ML, parsplana vitrectomy)

    Recruiting
    • Diabetic Retinopathy
    • Vitreomacular Traction
    • Methotrexate 25 MG/ML
    • parsplana vitrectomy
    • Minya, Minia, Egypt
      ophthalmology department, Minia university hospital
    Sep 8, 2023

    Wet Age-related Macular Degeneration Trial in Beijing (RC28-E, Aflibercept)

    Recruiting
    • Wet Age-related Macular Degeneration
    • Beijing, Beijing, China
      Beijing Hospital
    Feb 3, 2023

    CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea

    Active, not recruiting
    • AMD
    • Exudative Macular Degeneration
      • Bordeaux, France
      • +4 more
      Dec 2, 2022

      naïve Age-related Macular Degeneration Neovascular Type and

      Completed
      • Macular Degeneration
      • Data extraction from medical files
      • Brussels, Belgium
        CHU Brugmann
      Mar 7, 2022

      Retinal Disease, Retinitis Pigmentosa Trial in Riyadh (Subretinal administration of rAAV2-VMD2-hMERTKRecombinant

      Completed
      Has Results
      • Retinal Disease
      • Retinitis Pigmentosa
      • Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus
      • Riyadh, Saudi Arabia
        King Khaled Eye Specialist Hospital
      Jan 25, 2022

      Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in San Antonio (D-4517.2)

      Recruiting
      • Neovascular Age-related Macular Degeneration
      • Diabetic Macular Edema
      • Los Angeles, California
      • +11 more
      Jan 11, 2023

      Usher Syndrome, Retinitis Pigmentosa Trial in Portland, Paris (SAR421869)

      Terminated
      Has Results
      • Usher Syndrome
      • Retinitis Pigmentosa
      • Portland, Oregon
      • +1 more
      Mar 30, 2022

      Choroidal Blood Flow in Acute and Chronic Central Serous

      Recruiting
      • Central Serous Chorioretinopathy
      • Stavanger, Norway
        Stavanger University Hospital, Department of Ophthalmology
      Oct 18, 2022

      rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen

      Completed
      • Age Related Macular Degeneration
      • Bern, Switzerland
      • +1 more
      Nov 28, 2022

      Macular Holes Trial (3 Days of face-down positioning, 7 Days of face-down positioning)

      Not yet recruiting
      • Macular Holes
      • 3 Days of face-down positioning
      • 7 Days of face-down positioning
      • (no location specified)
      Aug 13, 2023

      Brolucizumab in Pre-treated nAMD in the Real-world Setting

      Not yet recruiting
      • Neovascular Age-related Macular Degeneration
      • Brolucizumab
      • (no location specified)
      Aug 8, 2022